Cargando…

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review

AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Sakuma, Kenji, Okuya, Makoto, Hatano, Masakazu, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411314/
https://www.ncbi.nlm.nih.gov/pubmed/34212530
http://dx.doi.org/10.1002/npr2.12192
_version_ 1783747277319307264
author Kishi, Taro
Sakuma, Kenji
Okuya, Makoto
Hatano, Masakazu
Iwata, Nakao
author_facet Kishi, Taro
Sakuma, Kenji
Okuya, Makoto
Hatano, Masakazu
Iwata, Nakao
author_sort Kishi, Taro
collection PubMed
description AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. RESULTS: We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment. CONCLUSION: The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results.
format Online
Article
Text
id pubmed-8411314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84113142021-09-03 Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review Kishi, Taro Sakuma, Kenji Okuya, Makoto Hatano, Masakazu Iwata, Nakao Neuropsychopharmacol Rep Micro Reports AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. RESULTS: We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment. CONCLUSION: The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results. John Wiley and Sons Inc. 2021-07-01 /pmc/articles/PMC8411314/ /pubmed/34212530 http://dx.doi.org/10.1002/npr2.12192 Text en © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Micro Reports
Kishi, Taro
Sakuma, Kenji
Okuya, Makoto
Hatano, Masakazu
Iwata, Nakao
Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title_full Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title_fullStr Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title_full_unstemmed Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title_short Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
title_sort outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: a chart review
topic Micro Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411314/
https://www.ncbi.nlm.nih.gov/pubmed/34212530
http://dx.doi.org/10.1002/npr2.12192
work_keys_str_mv AT kishitaro outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview
AT sakumakenji outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview
AT okuyamakoto outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview
AT hatanomasakazu outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview
AT iwatanakao outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview